Markets:

Overview

News

Currencies

International

Treasuries

Enanta Pharmaceuticals, Inc. - Common Stock (NQ:ENTA)

13.91 -0.51 (-3.54%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Enanta Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Today 7:00 EST

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025

November 17, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences

November 04, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025

October 20, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025

October 07, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

October 02, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

September 30, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock

September 30, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults

September 29, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults

September 26, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial and Administrative Officer Paul J. Mellett Jr.

September 03, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Participate in September Investor Conferences

August 21, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union

August 20, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025

August 11, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. “HCW@Home” Series

August 05, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Participate in Baird’s Biotech Discovery Series

July 15, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals’ Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus

June 11, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 27, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting

May 22, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025

May 12, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025

April 08, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

March 17, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV Symposium

March 12, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024

February 10, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 08, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit

December 24, 2024

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)

December 09, 2024

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)

December 06, 2024

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024

November 25, 2024

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)

September 26, 2024

From Enanta Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.